V
Vijay Reddy
Researcher at University of Florida
Publications - 63
Citations - 3693
Vijay Reddy is an academic researcher from University of Florida. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 24, co-authored 62 publications receiving 3392 citations. Previous affiliations of Vijay Reddy include University of Michigan & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann,Jeffrey H. Lipton,David H. Vesole,Pranatharthi H. Chandrasekar,Amelia Langston,Stefano R. Tarantolo,Hildegard Greinix,Wellington Morais de Azevedo,Vijay Reddy,Navdeep Boparai,Lisa D. Pedicone,Hernando Patino,Simon Durrant +12 more
TL;DR: Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD and was superior in preventing invasive aspergillosis and reducing the rate of deaths related toFungal infections.
Journal ArticleDOI
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Sally Arai,Mukta Arora,Tao Wang,Tao Wang,Stephen R. Spellman,Wensheng He,Daniel R. Couriel,Alvaro Urbano-Ispizua,Corey Cutler,Andrea Bacigalupo,Minoo Battiwalla,Mary E.D. Flowers,Mark B. Juckett,Stephanie J. Lee,Alison W. Loren,Thomas R. Klumpp,Susan E. Prockup,Olle Ringdén,Bipin N. Savani,Gérard Socié,Kirk R. Schultz,Thomas R. Spitzer,Takanori Teshima,Christopher Bredeson,David A. Jacobsohn,Robert J. Hayashi,William R. Drobyski,Haydar Frangoul,Gorgun Akpek,Vincent T. Ho,Victor Lewis,Robert Peter Gale,John Koreth,Nelson J. Chao,Mahmoud Aljurf,Brenda W. Cooper,Mary J. Laughlin,Jack W. Hsu,Peiman Hematti,Leo F. Verdonck,Melhelm M. Solh,Maxim Norkin,Vijay Reddy,Rodrigo Martino,Shahinaz M. Gadalla,Jenna D. Goldberg,Philip L. McCarthy,José A. Pérez-Simón,Nandita Khera,Ian D. Lewis,Yoshiko Atsuta,Richard F. Olsson,Richard F. Olsson,Wael Saber,Edmund K. Waller,Didier Blaise,Joseph Pidala,Paul J. Martin,Prakash Satwani,Martin Bornhäuser,Yoshihiro Inamoto,Daniel J. Weisdorf,Mary M. Horowitz,Steven Z. Pavletic +63 more
TL;DR: In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods and the mounting need for addressing this major late complication of transplantation in future research is underscores.
Journal ArticleDOI
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
Mary E.D. Flowers,Jane F. Apperley,Koen van Besien,Ahmet H. Elmaagacli,Andrew Grigg,Vijay Reddy,Andrea Bacigalupo,Hans-Jochem Kolb,Luis Fernando Bouzas,Mauricette Michallet,H. Miles Prince,Robert Knobler,Dennis Parenti,Jose Gallo,Hildegard T. Greinix +14 more
TL;DR: It is suggested that ECP may have a steroid-sparing effect in the treatment of cGVHD and was generally well tolerated.
Journal ArticleDOI
Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital.
WB Grow,Jan S. Moreb,D Roque,K Manion,Helen Leather,Vijay Reddy,S.A. Khan,K.J. Finiewicz,H Nguyen,Cornelius J. Clancy,Paulette Mehta,John R. Wingard +11 more
TL;DR: The data illustrate a shift toward a later occurrence of post-transplant IA, suggesting a need for close, prolonged surveillance in the outpatient environment and have important implications in an era of alternate donor transplants and more intense immunosuppression.
Journal ArticleDOI
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
Theresa Hahn,Philip L. McCarthy,Mei-Jie Zhang,Dan Wang,Mukta Arora,Haydar Frangoul,Robert Peter Gale,Gregory A. Hale,John T. Horan,Luis Isola,Richard T. Maziarz,Jon J. van Rood,Vikas Gupta,Joerg Halter,Vijay Reddy,Pierre Tiberghien,Mark R. Litzow,Claudio Anasetti,Stephen Pavletic,Olle Ringdén +19 more
TL;DR: This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD and identified several new factors that may facilitate individualized risk estimates and raise several interesting biologic questions.